A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

NCT07409103 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Active Rheumatoid Arthritis

Interventions

DRUG: ELV001 25 mg
DRUG: ELV001 75 mg
DRUG: ELV001 125 mg
DRUG: Placebo

Sponsor

Elevara Medicines Limited